A. Wang
Physics and Astronomy · University of Michigan
Publications
19
Citations
774
Est. group size
~1
Recurring co-author estimate
Active years
16
Publishing since 2011
Typically publishes in teams of ~15 · 0% small-team papers (≤3 authors) · across 4 venues
- Fidelity-Diversity Metrics for Text
arXiv (Cornell University) · 2026
- Fidelity-Diversity Metrics for Text
arXiv (Cornell University) · 2026
- 940TiP INTerpath-007: A phase II/III, adaptive, randomized study of neoadjuvant and adjuvant pembrolizumab (pembro) with V940 (mRNA-4157) for treatment of resectable locally advanced (LA) cutaneous squamous cell carcinoma (cSCC)
Annals of Oncology · 2024
- 1223P First-line lenvatinib (Len) + pembrolizumab (Pembro) + chemotherapy (Chemo) vs chemo in advanced/metastatic gastroesophageal adenocarcinoma: LEAP-015 safety run-in
Annals of Oncology · 2022
- P-81 Phase 3 study of MK4280A (coformulated favezelimab and pembrolizumab) versus standard of care in previously treated PD-L1–positive metastatic colorectal cancer (mCRC)
Annals of Oncology · 2022
- SO-13 Pembrolizumab in patients with advanced hepatocellular carcinoma (aHCC) previously treated with sorafenib: Updated data from the open-label, phase 2 KEYNOTE-224 study
Annals of Oncology · 2022
- A framework for quantifying uncertainty in DFT energy corrections
Scientific Reports · 2021
- 933P Updated results for pembrolizumab (pembro) monotherapy as first-line therapy for advanced hepatocellular carcinoma (HCC) in the phase II KEYNOTE-224 study
Annals of Oncology · 2021
- P-154 A randomized phase 3 study evaluating the efficacy and safety of first-line pembrolizumab plus lenvatinib plus chemotherapy compared with chemotherapy in patients with advanced/metastatic gastroesophageal adenocarcinoma: LEAP-015
Annals of Oncology · 2021
- A Framework for Quantifying Uncertainty in DFT Energy Corrections
ChemRxiv · 2021
- Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study
Annals of Oncology · 2020
- O-12 KEYNOTE-061: Response to subsequent therapy following second-line pembrolizumab or paclitaxel in patients with advanced gastric or gastroesophageal junction adenocarcinoma
Annals of Oncology · 2020
- Annals of Oncology×8
- arXiv (Cornell University)×4
- Applied Physics Letters×3
- Scientific Reports×1
- ChemRxiv×1
- Andrew Armstrong
Physics and Astronomy · The Ohio State University
- Andrew McAllister
Physics and Astronomy · University of Michigan
- Aaron R. Arehart
Physics and Astronomy · The Ohio State University
- Agnes Maneesha Dominic Merwin Xavier
Physics and Astronomy · The Ohio State University
- Arnob Ghosh
Physics and Astronomy · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile